Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.

Maha H A Hussain Bertrand Tombal Fred Saad Karim Fizazi Cora N SternbergE David CrawfordNeal D ShoreEvgeny KopyltsovArash Rezazadeh Kalebasty Martin Boegemann Dingwei Ye Felipe José Silva Melo CruzHiroyoshi SuzukiShivani KapurShankar SrinivasanFrank VerholenIris KussHeikki JoensuuMatthew R Smith

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)

In patients with high-volume and high-risk/low-risk metastatic hormone-sensitive prostate cancer, treatment intensification with darolutamide, androgen-deprivation therapy, and docetaxel increased OS with a similar AE profile in the subgroups, consistent with the overall population.

Keyphrases

phase iii
prostate cancer
clinical trial
open label
squamous cell carcinoma
small cell lung cancer
phase ii
radical prostatectomy
double blind
locally advanced
placebo controlled
randomized controlled trial
bone marrow
rectal cancer